3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pain
7
Neoplasms
3
Pain, Postoperative
2
Malignant Female Reproductive System Neoplasm
2
Hematologic Neoplasms
2
Emergencies
2
Agnosia
2
Uterine Cervical Neoplasms
1
Tumor Surgery
1
Sarcoma
1
Rectal Neoplasms
1
Pulmonary Nodule
1
Prostatic Neoplasms
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Pain, Intractable
1
Ovarian Neoplasms
1
Neuralgia
1
Neoplasm Metastasis
1
Mucositis
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intraoperative Complications
1
Ileus
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Duodenal Neoplasms
1
Diverticulosis, Colonic
1
Interventions
Sorafenib
42
Bevacizumab
26
Oxaliplatin
21
Radiosurgery
19
Gemcitabine
17
Fluorouracil
15
Hepatectomy
13
lenvatinib
12
Radiofrequency Ablation
11
Nivolumab
11
Cisplatin
11
Radiotherapy
10
Doxorubicin
10
Capecitabine
10
durvalumab
9
Leucovorin
9
Blood Specimen Collection
9
atezolizumab
8
Liver Transplantation
8
Everolimus
7
Electroporation
7
pembrolizumab
6
camrelizumab
6
Sunitinib
6
Immunohistochemistry
6
Cryosurgery
6
Carboplatin
6
tremelimumab
5
sintilimab
5
apatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liver Neoplasms
×
Hydromorphone
×
Clear all
NCT03715517
2026-02-05
SAFER-L
University of Manitoba
Phase NA
Recruiting
128 enrolled